J. E. Lancet

Randomized, phase IIb study of low-dose cytarabine and lintuzumab versus low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia

Mikkael A. Sekeres, J. E. Lancet, Brent L. Wood et al. · Haematologica · 2012 · 91 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Autotransplantation for relapsed or refractory Hodgkin’s disease: long-term follow-up and analysis of prognostic factors

J. E. Lancet, AP Rapoport, R.A. Brasacchio et al. · Bone Marrow Transplantation · 1998 · 60 citations

Medicine, Oncology, Surgery +16

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia

J. E. Lancet, G.J. Roboz, Larry D. Cripe et al. · Haematologica · 2014 · 28 citations · Full text

Medicine, Oncology, Pharmacology +17